Analgesics in Norway

Date: October 30, 2017
Pages: 22
Price:
US$ 990.00
Publisher: Euromonitor International Ltd
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A02F221CB56EN
Leaflet:

Download PDF Leaflet

Norway has an ageing population. According to the Norwegian Institute of Public Health, 30% of adults suffer from chronic pain, and this becomes more common with increasing age, probably mainly due to increased morbidity, although there is also evidence that the mechanisms which suppress pain, such as endorphins, are less effective at an elderly age, which may contribute to increased pain sensitivity.

Euromonitor International's Analgesics in Norway report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2012-2016, allowing you to identify the sectors driving growth. Forecasts to 2021 illustrate how the market is set to change.

Product coverage: Systemic Analgesics, Topical Analgesics/Anaesthetic.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
  • Get a detailed picture of the Analgesics market;
  • Pinpoint growth sectors and identify factors driving change;
  • Understand the competitive environment, the market’s major players and leading brands;
  • Use five-year forecasts to assess how the market is predicted to develop.
Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
Headlines
Prospects
the Ageing Population and Prevalence of Chronic Pain at Older Ages Boosts Sales of Adult Analgesics
Growth of Analgesics Depends on Future Regulations
Sales of Analgesics Will Grow Faster Outside of Chemists/pharmacists
Competitive Landscape
Weifa Remains the Clear Leader
Private Label and Generics Suffer
Weifa, Leader in Innovation, Launches A New Product Which Is Absorbed Faster
Category Data
  Table 1 Sales of Analgesics by Category: Value 2012-2017
  Table 2 Sales of Analgesics by Category: % Value Growth 2012-2017
  Table 3 Sales of Topical Analgesics/Anaesthetic by Format: % Value 2012-2017
  Table 4 NBO Company Shares of Analgesics: % Value 2013-2017
  Table 5 LBN Brand Shares of Analgesics: % Value 2014-2017
  Table 6 Forecast Sales of Analgesics by Category: Value 2017-2022
  Table 7 Forecast Sales of Analgesics by Category: % Value Growth 2017-2022
Executive Summary
Consumer Health Sales Develop in Line With Population Growth
2017 Growth in Line With the Review Period
Healthy Balance Between Domestic and Foreign Players
Growing Internet Sales Offer Convenience But Pose A Threat To Unwary Customers
Future Sales of Consumer Health in Line With Population Growth
Market Indicators
  Table 8 Consumer Expenditure on Health Goods and Medical Services: Value 2012-2017
  Table 9 Life Expectancy at Birth 2012-2017
Market Data
  Table 10 Sales of Consumer Health by Category: Value 2012-2017
  Table 11 Sales of Consumer Health by Category: % Value Growth 2012-2017
  Table 12 NBO Company Shares of Consumer Health: % Value 2013-2017
  Table 13 LBN Brand Shares of Consumer Health: % Value 2014-2017
  Table 14 Penetration of Private Label in Consumer Health by Category: % Value 2012-2017
  Table 15 Distribution of Consumer Health by Format: % Value 2012-2017
  Table 16 Distribution of Consumer Health by Format and Category: % Value 2017
  Table 17 Forecast Sales of Consumer Health by Category: Value 2017-2022
  Table 18 Forecast Sales of Consumer Health by Category: % Value Growth 2017-2022
Appendix
OTC Registration and Classification
Vitamins and Dietary Supplements Registration and Classification
Self-medication/self-care and Preventive Medicine
Switches
  Summary 1 OTC: Switches 2016-2017
Sources
  Summary 2 Research Sources
Skip to top


NRT Smoking Cessation Aids in Norway US$ 990.00 Oct, 2017 · 21 pages
Wound Care in Norway US$ 990.00 Oct, 2017 · 21 pages
Life Insurance in Norway US$ 350.00 Jan, 2014 · 35 pages

Ask Your Question

Analgesics in Norway
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: